Market Place
Sourcing Support
NLS Pharmaceutics CEO Issues Letter to Shareholders
11 Dec 2024 //
ACCESSWIRE
NLS Prices Private Placement Up To $1M At 15% Premium
04 Dec 2024 //
PR NEWSWIRE
NLS Pharma Reports Preclinical Data on Dual Orexin Agonists
03 Dec 2024 //
ACCESSWIRE
NLS Pharma Highlights Preclinical DOXA Program for Narcolepsy
18 Nov 2024 //
ACCESSWIRE
NLS Pharmaceutics Regains Nasdaq Compliance
28 Oct 2024 //
ACCESSWIRE
NLS Secures Patent In Japan For Mazindol ER For Heroin Dependence
21 Oct 2024 //
ACCESSWIRE
NLS Pharmaceutics Closes Private Placement For Nasdaq Compliance
15 Oct 2024 //
ACCESSWIRE
NLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to Merge
29 Jul 2024 //
ACCESSWIRE
NLS Pharmaceutics Announces Registered Direct Offering
28 Jun 2024 //
ACCESSWIRE
NLS Announces Promising Preclinical Results for Parkinson`s Disease Treatments
27 Jun 2024 //
ACCESSWIRE
Nasdaq Grants NLS Pharmaceutics` Request for Listing Extension
25 Jun 2024 //
ACCESSWIRE
NLS Pharmaceutics Announces New Patent For Orexin Agonists
12 Jun 2024 //
ACCESSWIRE
NLS Pharma: Mazindol Neuroprotection In Narcolepsy Rat Model
28 May 2024 //
ACCESSWIRE
Nls Nasdaq Staff Delisting: Additional Determination Letter Received
24 May 2024 //
ACCESSWIRE
NLS Pharmaceutics Gets Nasdaq Delisting Notice, Will Request Hearing
19 Apr 2024 //
ACCESSWIRE
NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering
22 Mar 2024 //
ACCESSWIRE
NLS Secures Global License for Non-Sulfonamide Dual Orexin Agonist Platform
20 Mar 2024 //
ACCESSWIRE
NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering
20 Mar 2024 //
ACCESSWIRE
NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event
14 Mar 2024 //
ACCESSWIRE
Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance
11 Mar 2024 //
ACCESSWIRE
NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq
23 Feb 2024 //
ACCESSWIRE
NLS Pharmaceutics CEO Issues Letter to Shareholders
29 Dec 2023 //
ACCESSWIRE
NLS Pharma Announces Agreement to Develop Dual Orexin Agonist Platform of Aexon
01 Dec 2023 //
ACCESSWIRE
NLS Pharmaceutics Announces Election of Additional Board Members
28 Nov 2023 //
ACCESSWIRE
NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit
27 Nov 2023 //
ACCESSWIRE
NLS Pharma Announces Selection of Strategic Partner and Securing a Bridge Loan
16 Nov 2023 //
ACCESSWIRE
NLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification
25 Oct 2023 //
ACCESSWIRE
NLS Pharmaceutics Announces Company Update on Strategic Partnerships
12 Oct 2023 //
ACCESSWIRE
NLS Pharmaceutics CEO Issues Letter to Shareholders
28 Aug 2023 //
ACCESSWIRE
NLS Pharmaceutics to Proceed with Phase 3 Clinical Program for Mazindol ER
03 Jul 2023 //
ACCESSWIRE
NLS Pharmaceutics Releases the Results from its Annual General Meeting
30 Jun 2023 //
ACCESSWIRE
NLS Pharmaceutics Announces Company Update Webcast
19 Jun 2023 //
ACCESSWIRE
NLS Pharmaceutics Announces Company Update Webcast
15 Jun 2023 //
ACCESSWIRE
NLS Pharmaceutics to Participate in the Healthcare Virtual Conference
15 Jun 2023 //
ACCESSWIRE
NLS Pharmaceutics Announces Positive Safety Data From In Vitro CYP450
14 Jun 2023 //
ACCESSWIRE
NLS Pharmaceutics Presents Latest Clinical and Preclinical Data at SLEEP 2023
04 May 2023 //
ACCESSWIRE
FDA approves NLS’ narcolepsy therapy Phase III programme
03 May 2023 //
CLINICAL TRIALS ARENA
NLS Receives Green Light from the USFDA to Proceed with Ph3 Program (AMAZE)
02 May 2023 //
BUSINESSWIRE
NLS Pharmaceutics Presents Latest Preclinical Pipeline Data at American Society
25 Apr 2023 //
ACCESSWIRE
NLS Announces Label Extension Study Six-Month Data for Quilience Mazindol ER
27 Mar 2023 //
ACCESSWIRE
NLS Pharmaceutics to Present at the 35th Annual Roth Conference
01 Mar 2023 //
ACCESSWIRE
NLS Announces Completion of Extension Study with Quilience(R) (Mazindol ER)
30 Jan 2023 //
ACCESSWIRE
NLS Pharma Regains Compliance with Nasdaq Stockholders` Equity Requirement
26 Jan 2023 //
ACCESSWIRE
NLS Pharmaceutics Announces Israeli Patent Grant Covering Mazindol
20 Dec 2022 //
ACCESSWIRE
NLS Pharma Announces Closing of Initial Tranche of US$10.0M Purchase Agreement
14 Dec 2022 //
ACCESSWIRE
NLS Pharmaceutics Announces Purchase Agreement with BVF Partners L.P.
07 Dec 2022 //
ACCESSWIRE
NLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification
07 Dec 2022 //
ACCESSWIRE
NLS Pharma Announces Notice of Allowance for U.S. Patent Covering Mazindol
01 Dec 2022 //
ACCESSWIRE
NLS Pharma Announces Launch of Paid for Named Patient Program with Mazindol ER
23 Nov 2022 //
ACCESSWIRE
NLS Pharmaceutics Successfully Appeals Nasdaq Delisting Notice
14 Nov 2022 //
ACCESSWIRE
NLS Pharmaceutics Provides Open Label Extension Study Update for Quilience
07 Nov 2022 //
NASDAQ
NLS Pharma Provides Open Label Extension Study Update for Quilience(R)
07 Nov 2022 //
ACCESSWIRE
U.S. FDA Grants Orphan Drug Designation (ODD) for Quilience(R) (Mazindol ER)
02 Nov 2022 //
ACCESSWIRE
